Bizarre Patents
An enclosure for small animals which is wearable on the front or back of an animate being.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187636 | Dosage forms for tamper prone therapeutic agents A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap d... | 05/29/2012 |
| 7972625 | Coated diclofenac tablets The invention relates to coated tablets comprising the pharmaceutically active substance diclofenac. Said tablets further comprise a single film coating. ... | 07/05/2011 |
| 7431944 | Delivery of multiple doses of medications Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release ... | 10/07/2008 |
| 7387791 | Liposome drug delivery This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal trac... | 06/17/2008 |
| 7337592 | Porous poly(vinyl acetal) resin body having a high degree of cleanliness, a process of preparing the same, and a method of storing the same A process of preparing and a method of storing porous poly (vinyl acetal) resin body. A method of storing the porous body involves keeping the porous body wet and free of contamination with organic substances, dissolved ions, and other fine particles. The storing me... | 03/04/2008 |
| 7338667 | Pharmaceutical formulation The present invention concerns an extended release formulation having an accelerating erosion and/or dissolution rate of the surface of the formulation. The formulation comprises a drug having low solubility in water dispersed or dissolved in at least one erasable h... | 03/04/2008 |
| 7332183 | Multilayer dosage forms containing NSAIDs and triptans The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independent... | 02/19/2008 |
| 7316821 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 01/08/2008 |
| 7316818 | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, a... | 01/08/2008 |
| 7314640 | Formulation and process for drug loaded cores The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. ... | 01/01/2008 |
| 7300668 | System for manufacturing controlled release dosage forms, such as a zero-order release profile dosage form manufactured by three-dimensional printing The present invention includes controlled release dosage forms and methods of designing and manufacturing dosage forms to obtain specific release profiles, for example, zero-order release profiles, escalating release profiles or decreasing release profiles. The dosa... | 11/27/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276250 | Sustained release formulations of oxymorphone Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of... | 10/02/2007 |
| 7276253 | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (... | 10/02/2007 |
| 7270831 | Orally administrable opioid formulations having extended duration of effect Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains ... | 09/18/2007 |
| 7267718 | Pullulan film compositions The invention concerns compositions based on pullulan and a setting system for the use in pharmaceutical, veterinary, food, cosmetic or other products like films for wrapping food, aspics or jellies, preferably for predosed formulations like soft or hard capsules. T... | 09/11/2007 |
| 7255878 | Stable benzimidazole formulation A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5,... | 08/14/2007 |
| 7235258 | Sustained-release formulations for treating CNS-mediated disorders Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which a... | 06/26/2007 |
| 7235253 | Powder containing physiologically active peptide A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to ... | 06/26/2007 |
| 7235260 | Pharmaceutical compositions of a sparingly soluble glycogen phosphorylase inhibitor Pharmaceutical compositions of a particularly effective sparingly soluble glycogen phosphorylase inhibitor are disclosed, as well as methods of making such compositions and dosage forms from such compositions. ... | 06/26/2007 |
| 7229642 | Amino acid modulated extended release dosage form Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extr... | 06/12/2007 |
| 7229643 | Oral 2-methyl-thieno-benzodiazepine formulation The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation. ... | 06/12/2007 |
| 7220762 | Methods for stabilizing benzimidazole compounds The present invention provides a method for stabilizing an oral solid formulation containing a benzimidazole-based compound or a physiologically acceptable salt thereof. That is, it provides a method for stabilizing a benzimidazole-based compound or a physiologicall... | 05/22/2007 |
| 7220434 | Dual-release compositions of a cyclooxygenase-2 inhibitor Pharmaceutical compositions are provided comprising one or more orally deliverable dose units, each comprising a selective cyclooxygenase-2 inhibitory drug of low water solubility, for example celecoxib, in an immediate-release fraction and a controlled-release, slo... | 05/22/2007 |
| 7214387 | Sustained release formulations of metformin The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a p... | 05/08/2007 |
| 7211582 | Methods for treating urticaria using descarboethoxyloratadine Methods are disclosed utilizing DCL, a metabolic derivative of loratadine, for the treatment of allergic rhinitis, and other disorders, while avoiding the concomitant liability of adverse side-effects associated with other non-sedating antihistamines. ... | 05/01/2007 |
| 7195769 | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation... | 03/27/2007 |
| 7172767 | Opioid agonist / antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide ... | 02/06/2007 |
| 7163696 | Pharmaceutical formulations The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a p... | 01/16/2007 |
| 7157095 | Multiple-delayed release antifungal product, use and formulation thereof An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-funga... | 01/02/2007 |
| 7135230 | Functional particle and preparing/plasma-treating method of the same At least one of a hollow particle 14, a porous particle 24, and a solid particle 34 having the pores 18, 28, 38 on the surface thereof is subjected to plasma irradiation under a reduced pressure while changing plasma irradiation intensity... | 11/14/2006 |
| 7129248 | Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone In certain embodiments the invention is directed to a process for preparing an oxycodone hydrochloride composition having less than 25 ppm of 14-hydroxycodeinone. ... | 10/31/2006 |
| 7125567 | Process for producing an oral sustained-release preparation of fasudil hydrochloride Disclosed is an oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof, the preparation comprising at least one sustained-release coated particle comprising a... | 10/24/2006 |
| 7125563 | Sustained release pharmaceutical preparations and methods for producing the same An extended release tablet comprising a core including albuterol sulfate and extended release agent; and an extended release coating on the core to provide for sustained release of the albuterol sulfate. ... | 10/24/2006 |
| 7122207 | High drug load acid labile pharmaceutical composition A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder select... | 10/17/2006 |
| 7122204 | Antibiotic composition with inhibitor Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. I... | 10/17/2006 |
| 7108866 | Chronotherapeutic diltiazem formulations and the administration thereof A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of D... | 09/19/2006 |
| 7105174 | Multiple-delayed release anti-neoplastic product, use and formulation thereof An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of an... | 09/12/2006 |
| 7101567 | Controlled release preparations having multi-layer structure Preparations whereby two or more drugs can be released separately at appropriate speeds depending on the disease or the release behaviors of one or more drugs can be precisely controlled, which consist of an outer layer wherein a water-soluble drug is dispersed in a... | 09/05/2006 |
| 7097967 | Method of predicting drug-food interaction The present invention provides a method of predicting a food-drug interaction in vivo, in the case of an orally administered drug interactive with digestive enzymes in the gastrointestinal tract, by measuring the activity of the drug to the digestive enzymes in vitr... | 08/29/2006 |
